Tango drops USP1 inhibitorUSP1 inhibitor over liver toxicity in patients during phase 1 trial
License out/inPhase 1
Preview
Source: FierceBiotech
“While disappointing, we believe this is the right decision given the data at hand,” Tango's CEO said.
Tango Therapeutics has discarded one of its cancer drugs on the dancefloor after the USP1 inhibitorUSP1 inhibitor was linked to reports of liver toxicity in a phase 1 trial.
The biotech had been testing the safety and efficacy of the candidate, dubbed TNG348, in a phase 1/2 study in patients with BRCA1/2-mutant and other HRD+ cancers. The plan had been to add AstraZeneca’s and Merck & Co.’s PARP inhibitor Lynparza into the mix as a combo treatment, but the study never made it that far.
Instead, Tango has decided to end the trial—and the TNG348 program entirely—after grade 3/4 “liver function abnormalities” were observed in patients who continued on the study for longer than eight weeks. A grade 4 event is considered life-threatening.
“Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial,” Tango’s CEO Barbara Weber, M.D., said in the May 23 release.
“While disappointing, we believe this is the right decision given the data at hand,” Weber added.
USP1, a deubiquitinating enzyme that regulates DNA damage response, is one of a number of emerging targets for synthetic lethality, an approach to killing cancer cells that PARP inhibitorsPARP inhibitors such as Lynparza have helped put on the map over the past decade. While PARP inhibitorsPARP inhibitors have validated the concept, they are unable to trigger responses in all patients and are vulnerable to resistance even when they are initially effective.
Last year, Roche inked a deal to secure an exclusive global license to KSQ Therapeutics’ early-phase USP1 inhibitorUSP1 inhibitor.
With Tango’s own USP1 ambitions up in smoke, Weber said the company will focus resources on its remaining portfolio, which is headed up by a PRMT5 program. The lead candidate, TNG908, is being assessed in a phase 1/2 in patients with MTAP-deleted tumorsMTAP-deleted tumors. Another PRMT5 drug, TNG462, is also in phase 1/2 development for various tumor types.
Tango also has a dance partner in the form of Gilead, with a long-standing collaboration that stretches to 15 immuno-oncology targets.
The biotech's shares were trading down premarket by 5.3% to $7 as of 7:12 am ET on Thursday morning.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.